MAP2K1 and glioblastoma: High <i>RNF135</i> expression was also linked to greater sensitivity to Selumetinib, a selective MEK1/2 inhibitor that targets the MAPK/ERK pathway, according to drug sensitivity analysis.<h4>Conclusions</h4><i>RNF135</i> defines a TAM phenotype in GBM that is both immunologically active and immunosuppressive.